Aveo Fails to Win FDA Panel Nod for Kidney Cancer Drug

Aveo Pharmaceuticals Inc. failed to win the backing of U.S. regulatory advisers for its lead product candidate, a kidney cancer drug, after the panelists questioned whether it was as effective as existing treatments. Aveo shares lost half their value, falling the most in three years, after the panel’s vote.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.